In a bid to help the immune system of autoimmune disease patients reset, a San Francisco startup startup has raised $120 ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, ...

We are delighted to welcome Kristen and Nancy to our Board of Directors,” said Tom King, Executive Chairman of Achieve’s Board of Directors. “Their wealth of knowledge and experience in strategic ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Neuberg Diagnostics, a diagnostics chain headquartered in India, raised Rs 940 crore from Kotak Alternate Asset Managers Ltd.

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

Shingrix in 2017 received US FDA approval to prevent shingles in adults aged 50 and older. Since 2021, it has been approved for use in immunocompromised patients aged 18 and up. GSK estimates around ...